Clinical Trial

Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology Genitourinary Cancers Symposium

Flatiron’s high-quality real-world data and innovative artificial intelligence-based extraction are generating novel learnings on treatment safety and patterns for people…

11 months ago

Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology Genitourinary Cancers Symposium

Flatiron’s high-quality real-world data and innovative artificial intelligence-based extraction are generating novel learnings on treatment safety and patterns for people…

11 months ago

RefleXion Expands Access to SCINTIX Therapy with First Freestanding Cancer Center

HAYWARD, Calif.--(BUSINESS WIRE)--#RefleXion--RefleXion Medical, a theranostic oncology company, today announced the scheduled installation of its RefleXion® X1 platform with SCINTIX®…

11 months ago

Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors

Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

11 months ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Experienced Healthcare Executive to Lead Finance OrganizationSEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to…

11 months ago

Capricor Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based…

11 months ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will…

11 months ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2…

11 months ago

Oncocyte Prices $29.1 Million Equity Offering

Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial LaunchStrategic Partner Bio-Rad Invests, Boosts Support for Trial…

11 months ago

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer 

Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology…

11 months ago